A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in Taiwan
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Kuo-Ting Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. No.138, Sheng Li…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cheng Kung University Hospital, DAIICHI SANKYO COMPANY, LIMITED, AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: The binary classification of human epidermal growth factor receptor 2 (HER2) as HER2-positive [immunohistochemistry (IHC) 2+/in situ hybridization (ISH)+ or 3+] or HER2-negative (IHC 0, 1+, or 2+/ISH-) has been reassessed due to the efficacy of an anti-HER2 antibody-drug conjugate-Trastuzumab Deruxtecan in HER2-low (IHC 1+ or 2+/ISH-) unresectable/metastatic breast cancer (mBC) patients. However, little is known about the prevalence and outcomes of HER2-low mBC in Taiwan. METHODS: This retrospective study rescored archived HER2 IHC slides of HER2-negative unresectable/mBC patients diagnosed from 2017 to 2020. The HER2-low prevalence (among HER2-negative), clinicopathological characteristics, treatments, and outcomes of HER2-low unresectable/mBC patients were investigated. RESULTS: Of the rescored HER2-negative cohort, HER2-low prevalence was 61.2 % (186/304) and slightly higher in slides tested by non-Ventana 4B5 assays (vs. Ventana 4B5) and slides from metastatic sites (vs. primary tumors). The overall percentage agreement between historical and rescored IHC was high (90.1 %). For HR+/HER2-low patients, endocrine therapies were frequently used in the first two lines of treatment, while chemotherapy was more common after the second-line treatment. Chemotherapy was the predominant treatment for HR-/HER2-low patients. Time to next treatment (TTNT) and overall survival (OS) since the first-line systemic therapy were longer in the HR+/HER2-low (N = 138) compared to HR-/HER2-low (N = 48) cohorts (median TTNT: 7.6 vs. 4.8 months; median OS: 37.7 vs. 18.8 months). CONCLUSION: This study suggested that two-thirds of HER2-negative unresectable/mBC patients in Taiwan were HER2-low. Reassessing the HER2 status of HER2-negative patients could improve treatment strategies with the evolving HER2 classification paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. No.138, Sheng Li Rd., Tainan 704, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. No.1, Changde St., Zhongzheng Dist., Taipei City 100229, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan Universi…
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan; College of Nursing, National Taipei Univer…
- Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. No.8, Chung Shan S. Rd., Zhongzheng Dist., Taipei City 100226, Taiwan.
- Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. No.138, Sheng Li Rd., Tainan 704, Taiwan.
- Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan. No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City 11217, Taiwan; Division of Medical Oncology, Department of Oncology, Taipei…
Förderung
- National Cheng Kung University Hospital
- DAIICHI SANKYO COMPANY, LIMITED
- AstraZeneca
Zitieren
APA
Lee, K. T., Huang, P. H., Hsu, C. Y., Lee, Y. H., Chen, H. W., Lu, Y. S., Lai, J. I., Chao, T. C., Liu, C. Y., Huang, C. C., Tsai, Y. F., Tseng, L. M., Yang, W. C., Huang, Y. T., Huang, C. Y., & Lin, Y. C. (2025). A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in Taiwan. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100893
Vancouver
Lee KT, Huang PH, Hsu CY, Lee YH, Chen HW, Lu YS, et al. A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in Taiwan. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100893
BibTeX
@article{Lee2025,
author = {Lee, Kuo-Ting and Huang, Po-Hsiang and Hsu, Chih-Yi and Lee, Yi-Hsuan and Chen, Hui-Wen and Lu, Yen-Shen and Lai, Jiun-I and Chao, Ta-Chung and Liu, Chun-Yu and Huang, Chi-Cheng and Tsai, Yi-Fang and Tseng, Ling-Ming and Yang, Wei-Chen and Huang, Yu-Ting and Huang, Ching-Ya and Lin, Yu-Ciou},
title = {A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in Taiwan},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100893}
}
EUVIMED